Haleon Pakistan Limited Stock

Equities

HALEON

PK0112101016

Pharmaceuticals

End-of-day quote Pakistan S.E. 18:00:00 2024-07-17 EDT 5-day change 1st Jan Change
298.6 PKR -1.27% Intraday chart for Haleon Pakistan Limited -3.67% +76.65%

Financials

Sales 2021 24.16B 86.91M 119M Sales 2022 27.51B 98.94M 136M Capitalization 19.19B 69.01M 94.6M
Net income 2021 2.13B 7.68M 10.52M Net income 2022 325M 1.17M 1.6M EV / Sales 2021 1.04 x
Net cash position 2021 3.09B 11.11M 15.23M Net cash position 2022 3.28B 11.8M 16.18M EV / Sales 2022 0.58 x
P/E ratio 2021
13.2 x
P/E ratio 2022
59 x
Employees 478
Yield 2021 *
-
Yield 2022
-
Free-Float 14.2%
More Fundamentals * Estimated data
Dynamic Chart
Haleon Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Haleon Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Haleon Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Haleon Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Haleon Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Unilever Looking to Reposition Portfolio After GSK Consumer Healthcare Approach -- Update DJ
Unilever Looking to Reposition Portfolio Into Higher Growth Categories DJ
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Glaxosmithkline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
GlaxoSmithkline Consumer Healthcare Pakistan Limited Announces Change of Chief Executive Officer CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Recommends Cash Dividend CI
More news
1 day-1.27%
1 week-3.67%
Current month+0.40%
1 month+4.48%
3 months+29.58%
6 months+48.69%
Current year+76.65%
More quotes
1 week
298.00
Extreme 298
310.00
1 month
270.00
Extreme 270
319.00
Current year
179.00
Extreme 179
319.00
1 year
120.00
Extreme 120
319.00
3 years
120.00
Extreme 120
319.00
5 years
120.00
Extreme 120
337.00
10 years
65.05
Extreme 65.0548
529.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-03-31
Director of Finance/CFO - 14-12-31
Investor Relations Contact - 20-05-30
Members of the board TitleAgeSince
Director/Board Member - 21-03-02
Director/Board Member - 16-06-22
Chief Executive Officer - 21-03-31
More insiders
Date Price Change Volume
24-07-17 298.6 -1.27% 8 585
24-07-15 302.4 -1.50% 7,680
24-07-12 307 -0.71% 4,341
24-07-11 309.2 -0.24% 6,041
24-07-10 310 +0.33% 20,569

End-of-day quote Pakistan S.E., July 17, 2024

More quotes
Haleon Pakistan Limited, formerly Glaxosmithkline Consumer Healthcare Pakistan Limited, is a Pakistan-based healthcare company. The Company's product portfolio consists of five categories, namely oral health, pain relief, respiratory health, digestive health, and other and vitamins, minerals and supplements (VMS). Its geographical segment consists of North America; Europe, Middle East and Africa (EMEA), and Latin America (LatAm), and Asia-Pacific (APAC). The Brands under Oral Health include Sensodyne, Parodontax, Polident, and Biotene. Its Vitamins, Minerals and Supplements offers a portfolio of brands, such as Centrum, a multivitamin and mineral brand; calcium supplements through its Caltrate brand, and vitamin C supplements through Emergen-C. The Brands under Respiratory consists of Otrivin, Theraflu, and Flonase. The Company's Pain Relief product includes Panadol, Voltaren, and Advil brands. Its portfolio digestive health brands consist of Eno, Tums, and Fenistil.
More about the company
  1. Stock Market
  2. Equities
  3. HALEON Stock